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Biologic TNF‑α inhibitors reduce microgliosis,
neuronal loss, and tau phosphorylation
in a transgenic mouse model of tauopathy
Weijun Ou1, Joshua Yang2, Juste Simanauskaite3, Matthew Choi4, Demi M. Castellanos2, Rudy Chang1,
Jiahong Sun1, Nataraj Jagadeesan1, Karen D. Parfitt3, David H. Cribbs5 and Rachita K. Sumbria1,6*

Abstract
Background: Tumor necrosis factor-α (TNF-α) plays a central role in Alzheimer’s disease (AD) pathology, making
biologic TNF-α inhibitors (TNFIs), including etanercept, viable therapeutics for AD. The protective effects of biologic
TNFIs on AD hallmark pathology (Aβ deposition and tau pathology) have been demonstrated. However, the effects
of biologic TNFIs on Aβ-independent tau pathology have not been reported. Existing biologic TNFIs do not cross the
blood–brain barrier (BBB), therefore we engineered a BBB-penetrating biologic TNFI by fusing the extracellular domain
of the type-II human TNF-α receptor (TNFR) to a transferrin receptor antibody (TfRMAb) that ferries the TNFR into the
brain via receptor-mediated transcytosis. The present study aimed to investigate the effects of TfRMAb-TNFR (BBBpenetrating TNFI) and etanercept (non-BBB-penetrating TNFI) in the PS19 transgenic mouse model of tauopathy.
Methods: Six-month-old male and female PS19 mice were injected intraperitoneally with saline (n = 12), TfRMAbTNFR (1.75 mg/kg, n = 10) or etanercept (0.875 mg/kg, equimolar dose of TNFR, n = 10) 3 days/week for 8 weeks.
Age-matched littermate wild-type mice served as additional controls. Blood was collected at baseline and 8 weeks
for a complete blood count. Locomotion hyperactivity was assessed by the open-field paradigm. Brains were examined for phosphorylated tau lesions (Ser202, Thr205), microgliosis, and neuronal health. The plasma pharmacokinetics
were evaluated following a single intraperitoneal injection of 0.875 mg/kg etanercept or 1.75 mg/kg TfRMAb-TNFR or
1.75 mg/kg chronic TfRMAb-TNFR dosing for 4 weeks.
Results: Etanercept significantly reduced phosphorylated tau and microgliosis in the PS19 mouse brains of both
sexes, while TfRMAb-TNFR significantly reduced these parameters in the female PS19 mice. Both TfRMAb-TNFR and
etanercept treatment improved neuronal health by significantly increasing PSD95 expression and attenuating hippocampal neuron loss in the PS19 mice. The locomotion hyperactivity in the male PS19 mice was suppressed by
chronic etanercept treatment. Equimolar dosing resulted in eightfold lower plasma exposure of the TfRMAb-TNFR
compared with etanercept. The hematological profiles remained largely stable following chronic biologic TNFI dosing
except for a significant increase in platelets with etanercept.
Conclusion: Both TfRMAb-TNFR (BBB-penetrating) and non-BBB-penetrating (etanercept) biologic TNFIs showed
therapeutic effects in the PS19 mouse model of tauopathy.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that was first discovered in 1906 by
the German clinical psychiatrist and neuroanatomist,
Aloïs Alzheimer [1]. The neuropathological alterations
reported by Alzheimer in 1906 constitute the main pathological hallmarks of AD today: extracellular deposition
of amyloid-beta (Aβ)-containing plaques and intracellular tau-containing neurofibrillary tangles in the brain [2].
While the accumulation of Aβ plaques in the brain is a
characteristic of AD pathology, abnormal intracellular
accumulation of tau lesions is observed in several neurodegenerative disorders, known as tauopathies [3].
Apart from the predominant role of Aβ and tau pathology in AD, neuroinflammation has emerged as a driver
and an accelerator of AD pathology [4–6], and therefore
provides a broad window of opportunity (from early to
late-stage AD) for therapeutic intervention. Among the
pro-inflammatory mediators, TNF-α is one of the main
inflammatory cytokines involved in initiating and propagating an inflammatory response [7]. Both clinical and
preclinical studies support the role of peripheral and central nervous system (CNS) TNF-α in AD, and elevated
TNF-α levels were observed in the serum [8, 9] and postmortem brains of AD patients and AD mouse models [10,
11]. Furthermore, serum TNF-α levels correlated with
disease progression in AD patients [9]. Global TNF-α
receptor 1 (TNFR-1) knock-out prevented Aβ generation
and learning deficits in the APP23 AD mice [12]. Direct
application of TNF-α to cell culture preparations, or CNS
administration of TNF-α, increased Aβ production, tau
phosphorylation, and synaptic dysfunction [13–17], and
accelerated disease progression and cognitive decline
[18]. Similarly, peripheral TNF-α modulated AD pathology in mouse models [19, 20]. Adding to this, TNF-α
polymorphisms linked with increased TNF-α production
were found to be associated with late-onset AD [21].
Several studies report the effects of the existing FDAapproved biologic TNF-α inhibitors on AD pathology
both in humans and preclinical models. For example,
infliximab, a chimeric anti-TNF-α antibody, significantly
reduced cognitive deficits in a female AD patient and significantly reduced Aβ- and tau-pathology and memory
impairment in AD mouse models, following intrathecal and intracerebroventricular administration [22–24],
respectively. Similarly, perispinal etanercept, a fusion
protein of the extracellular domain of the type-II TNFR
and human IgG1 Fc-domain, improved cognitive deficits

in AD patients [25]. Accordingly, intrahippocampal
injection of dominant-negative TNF-α inhibitors reduced
Aβ pathology in the 3xTg mouse model [26]. Recently,
intracerebroventricular injection of a nanobody directed
against the TNFR-1 was protective in two mouse models of amyloidosis [27]. One commonality among the
aforementioned studies is the invasive route of injection
used to evaluate the CNS effects of these biologic TNF-α
inhibitors due to their limited blood–brain barrier (BBB)
penetration. For example, the brain uptake of etanercept
was found to be equal to that of a human IgG control
[28].
Tau protein belongs to the family of microtubule-associated proteins, has a high binding affinity for microtubules, and plays an important role in microtubule
stabilization for optimal neuronal function [29]. Tauopathies, including AD, are characterized by the aggregation
of hyperphosphorylated tau protein, which is strongly
correlated with neuroinflammation [30, 31]. Recent studies have shown that microglial activation and release of
pro-inflammatory cytokines exacerbate tau pathology,
independent of Aβ pathology [31, 32], and that antiinflammatory strategies can reduce tau pathology in mice
[33, 34]. Despite a large body of literature looking at the
effects of TNF-α inhibition on AD pathology, the effects
of TNF-α inhibition on Aβ-independent tau pathology
have not been reported.
To study the effects of direct CNS TNF-α blockage via a non-invasive injection route, we engineered a
BBB-penetrating biologic TNF-α inhibitor by fusing the
extracellular domain of the type-II TNFR (decoy TNFR)
to a transferrin receptor antibody (TfRMAb) for BBB
penetration [35, 36]. The TfRMAb-TNFR fusion protein
binds to the BBB TfR and enters the brain via receptormediated transcytosis. The resulting brain concentrations of the TfRMAb-TNFR are > 40-fold higher than
that of a non-TfR targeting IgG [36]. Our previous work
showed that this BBB-penetrating TNF-α inhibitor
reduces Aβ plaques, insoluble Aβ1-42, BBB-disruption,
brain endothelial activation, and cognitive memory deficits in the APP/PS1 double transgenic AD mouse model
of amyloidosis [37]. Overall, the BBB-penetrating TNF-α
inhibitor had better therapeutic indices than etanercept,
a non-BBB-penetrating TNF-α inhibitor [28] expected
to modulate only peripheral but not CNS TNF-α, in the
mouse model of amyloidosis [37]. However, the effects of
these biologic TNF-α inhibitors on tau pathology are currently unknown.
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Based on the above, the goal of the current investigation was to examine the effects of peripheral and CNS
TNF-α inhibition on tau pathology using the P301S
mutant tau transgenic mouse model of tauopathy (line
PS19). For this, we first evaluated the effect of the biologic TNF-α inhibitors (etanercept: non-BBB-penetrating
and TfRMAb-TNFR: BBB-penetrating) on tau phosphorylation, microgliosis, and neuronal health. We further
assessed the effect of the biologic TNF-α inhibitors on
the hyperactive phenotype of the PS19 mice using the
open-field test. To gain insight into the differential therapeutic effects of the two biologic inhibitors, we examined
the plasma pharmacokinetics of these biologics in mice.
Finally, the overall hematologic safety of chronic biologic
TNF-α inhibitor dosing was evaluated by performing a
complete blood count in the PS19 mice.

Methods
Fusion protein

TfRMAb-TNFR was produced via transient expression in
CHO-K1 cells, and cell supernatants were collected for
protein A purification followed by size exclusion chromatography (WuXi Biologics, NJ, USA), as described previously [36]. The final protein purity was > 96%, and the
target protein was verified by Western blot. Etanercept
was obtained from International Laboratory USA (CA,
USA). The affinity of the TfRMAb-TNFR fusion protein
to the mouse TfR and human TNF-α was confirmed
through ELISA (Additional file 1: Supplemental Methods, Additional file 2: Fig. S1A, B). TNF-α inhibitory
effects were confirmed in vitro using induced pluripotent stem cell (iPSC)-derived human brain microvascular
endothelial cells (ihBMECs; Additional file 1: Supplemental Methods, Additional file 2: Fig. S1C, D). Both the
TfRMAb-TNFR fusion protein and etanercept were formulated in 100 mM glycine, 150 mM NaCl, 28 mM Tris,
and 0.01% Polysorbate 80, pH = 6.42, sterile filtered, and
stored at − 80 °C until use.
Chronic dosing in a mouse model of tauopathy

Animal studies were performed on hemizygous Tg(PrnpMAPT*P301S)PS19Vle (PS19) mice (6 months old at
the start of the study, Jackson Laboratories, ME, USA)
in compliance with University Laboratory Animal
Resources under protocols approved by the University
of California, Irvine, Institutional Animal Care and Use
Committee. Mice were provided constant access to food
and water and were maintained under a 12 h light/12 h
dark cycle. Mice were injected intraperitoneally (IP)
three days per week for 8 weeks with saline (PS19Saline; n = 12, female = 7, male = 5), TfRMAb-TNFR
(PS19-TfRMAb-TNFR; 1.75 mg/kg, n = 10, female = 5,
male = 5), or etanercept (PS19-Etanercept; 0.875 mg/
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kg, n = 10, female = 5, male = 5). These are equimolar
doses of TfRMAb-TNFR and etanercept since the TNFR
domain comprises ~ 50% of etanercept and ~ 26% of the
TfRMAb-TNFR fusion protein based on amino acid
sequence [36, 38]. Age-matched noncarrier wild-type
(WT) littermates (n = 12, female = 6, male = 6) received
equivalent volume of saline via the IP route (Fig. 1A). All
the mice were evaluated for signs of immune response
(general appearance, spontaneous locomotion, and posture) after each injection, and body weights were checked
weekly. Blood was collected at baseline and 8 weeks after
treatment for a complete blood count (Molecular Diagnostic Services, Inc., CA, USA). At the end of 8 weeks,
mice were subjected to the open-field paradigm that was
performed over a week, anesthetized with a lethal dose
of Euthasol (150 mg/kg, IP), and perfused with ice-cold
phosphate buffer saline (PBS). Brains were harvested, and
hemi-brains were fixed in 4% paraformaldehyde (PFA)
for immunostaining or were frozen in dry ice for Western
blotting (Fig. 1A).
Open‑field testing

Since the PS19 mice consistently demonstrate a hyperactivity phenotype compared to cognitive deficits [39–
41], we used the open-field test to measure locomotion
hyperactivity. The open-field test was performed after 8
weeks of treatment (during week 9) as described previously [42–44]. Briefly, mouse movements were recorded
for 5 min after placing in a white open box (72 cm x
72 cm with 36 cm walls). Mean speed and total distance
were measured for locomotion evaluation. A center
square, measuring 36 cm × 36 cm was drawn in the open
box to measure time in the center. Time in the center was
used as a measure of anxiety in mice. All analysis was
performed using the SMART 3.0 Video Tracking Software (Panlab, Harvard Apparatus, MA, USA).
Cryosectioning

The right-cerebral hemi-brain of each mouse was immersion-fixed with 4% PFA in PBS for 24 h, followed by serial
incubation in 10%, 20%, and 30% sucrose solution at
4 °C for 24 h each, which was followed by freezing. The
frozen brain tissues were mounted in Tissue-Tek OCT
compound (Fisher Scientific, MA, USA), and sliced into
20-μm-thick sagittal sections at − 25 °C using a cryostat
(Micron Instruments, CA, USA). Five sections (600 µm
apart) per mouse were used for immunostaining and histology as described below.
Phospho‑tau (pTau; Ser202, Thr205) and Iba‑1
immunostaining

Free-floating sagittal brain sections were washed three
times for 2 min in PBS and blocked with 0.5% bovine
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Fig. 1 Effect of TNF-α inhibitors on pTau (Ser202, Thr205) in the PS19 mice. Schematic showing the experimental timeline for treatment and sample
processing of the PS19 mice. Figure was prepared using BioRender.com (A). AT8-positive area in different brain regions in male (B) and female (C)
mice. The overall AT8-positive area, which is an average of the regional AT8-positive area, was significantly reduced by etanercept in both sexes and
by TfRMAb-TNFR in female mice (B, C). Representative images of AT8-positive pTau in PS19 mice (D). The thumbnail brain section images showing
the hippocampus (red box) and amygdala (black box) in D are taken from Allen Institute. Scale bar = 150 μm. Data are presented as mean ± SEM
of 10–12 mice per treatment group (5–7 per sex per group). Two-way ANOVA with repeated measures with Holm–Sidak’s post hoc test was used to
compare to PS19-Saline controls. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

serum albumin (BSA) in PBS containing 0.3% Triton X-100 (TX100) for 60 min at room temperature.
Adjacent tissue sections were incubated with either
0.2% biotin-conjugated pTau monoclonal antibody
(AT8 antibody to detect tau phosphorylated at ser202,
thr205; Thermo Fisher Scientific, MA, USA) or 0.5 µg/
mL anti-Iba-1 rabbit antibody (to detect microgliosis)

in PBS containing 0.3% TX100 and 0.5% BSA overnight
at 4 °C. The tissue sections were then washed three
times in PBS for 5 min and incubated in the dark with
0.5% AlexaFluor 594 conjugated streptavidin antibody
(Biolegend; CA, USA) for pTau detection or with 0.1%
AlexaFluor 488 donkey anti-rabbit IgG (Biolegend;
CA, USA) in PBS containing 0.3% TX-100 and 0.5%
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BSA for 2 h at room temperature. The sections were
then washed three times in PBS for 10 min and quickly
dipped in distilled water to remove the salts. The sections were mounted onto glass slides, cover-slipped
with Vectamount aqueous mounting media (Vector
Laboratories, CA, USA), and sealed with nail polish.
Slides were stored at 4 °C until imaging.
pTau (Ser202, Thr205) and Iba‑1 quantification

The fluorescent staining was analyzed using a Leica
TCS SP5 Confocal Microscope (Leica, NJ, USA). For
immunostaining, five distinct brain sections (600 µm
apart) for each mouse were used for analysis. For each
brain section, two regions in the cerebral cortex, one
or two regions in the hippocampus, one region in the
entorhinal cortex, and one region in the amygdala were
examined and imaged at a 10 × magnification. For Iba-1
immunostaining, for each brain section, three regions
in the cortex, two regions in the hippocampus, two
regions in the entorhinal cortex, and one region in
the amygdala was imaged at a 10 × magnification with
3 × digital zoom. The digitized images were analyzed
using the NIH ImageJ (version 1.53e, MD, USA) using
a threshold setting to calculate tissue area positive for
the AT8 or Iba-1. For this, immunofluorescent images
were converted to 16-bit and inverted to grayscale.
Threshold values of images were manually calibrated to
eliminate background noise. After adjusting the threshold, the “analyze” function was used to report the tissue
area positive for AT8 or Iba-1. The AT8 or Iba-1-positive area was expressed as a percentage of the brain
tissue analyzed area. The stain positive area of each
brain region (cortex, hippocampus, entorhinal cortex,
and amygdala) was averaged for each mouse to give the
‘overall’ stain positive area. For microglia number quantification, each Iba-1-stained image was manually read
to count the number of microglia per image using NIH
ImageJ. For each brain region, the microglia counts
were summed to give the total number of microglia per
region per mouse. The overall number of microglia represents the sum of the microglia in each brain region
per mouse. Additionally, microglial soma size in pixel
units was determined in Iba-1-stained images of each
region using NIH ImageJ by converting images to 8-bit,
inverting to grayscale, and using the despeckle function
to highlight the soma in the images. A threshold setting
of > 10-pixel units was used to eliminate background
signal detection. The sum of the microglia from all the
brain regions was determined for each mouse to calculate the total number of microglial < 50- and > 50-pixel
units per mouse. All the NIH ImageJ analysis was
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performed by two readers blinded to the experimental
groups.
Hippocampal neuronal loss quantification

Hippocampal neuronal loss was determined in six mice
per treatment group (3 mice per sex). Three 20 µm sagittal mouse brain sections (600 µm apart and adjacent
to the sections selected for AT8 immunostaining) per
mouse were mounted on positive glass slides and allowed
to dry overnight. Hematoxylin and Eosin (H&E) staining was performed by consecutive dips in acetal staining jars (Simport, Quebec, Canada) as follows: 30 s in
distilled water, 10 min in filtered Mayer’s Hematoxylin
(Fisher Scientific, MA, USA), 30 s in tap water, 30 s in
Scott’s tap water/bluing reagent (10 g anhydrous M
 gSO4,
2 g NaHCO3, 1L tap water), 30 s in tap water, 4 min in
Eosin Y (0.5% aqueous solution; Sigma Aldrich, MO,
USA), 1 min in 95% ethanol, followed by 1 min in 100%
ethanol. The slides received a final dip in xylene (Sigma
Aldrich, MO, USA). Slides were cover-slipped with Permount mounting media (Fisher Scientific, MA, USA) and
imaged using a light microscope (Motic, British Columbia, Canada). Different hippocampal regions (Dentate
Gyrus (DG), CA1, CA2, and CA3) were imaged at a
10 × magnification, and the area occupied by the H&Estained hippocampal neurons (µm2) of the granule cell
layer in the DG and pyramidal layer in the CA1-3 regions
was manually outlined and quantified using NIH ImageJ
(version 1.53e, MD, USA) by a reader blinded to the
experimental groups. The total hippocampal neuronal
cell area per section was obtained by adding the regional
cell areas.
Western blot

Protein was extracted from the left frozen hemi-brains
using the radio-immunoprecipitation assay (RIPA) buffer
with Pierce Protease Inhibitor (Thermo Fisher Scientific, MA, USA) for Western blot as previously described
[44–46]. Briefly, pulverized brains were homogenized in
2 volumes of RIPA (25 mM Tris–HCl, pH 7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS) with 5 mM EDTA) and centrifuged at 20,800 × g for 20 min at 4 °C. The supernatants
were collected and processed with 4 × Laemmli buffer
(Bio-Rad, CA, USA) with 10% beta-mercaptoethanol followed by boiling for 10 min. Protein samples (30–50 μg)
were separated on 4–20% SDS-ready precast gels (BioRad, CA, USA) and transferred to polyvinylidene fluoride membranes (Bio-Rad, CA, USA). Membranes were
sequentially subjected to blocking in Tris-buffered saline
(TBS) containing 5% non-fat milk for 1 h at room temperature and probed with the mouse anti-PSD95 primary
antibody (a marker of synaptic/neuronal health) (1:1000
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in 3% non-fat milk, Santa Cruz Biotechnology, TX, USA)
overnight at 4 °C followed by washing with TBS with
0.1% Tween-20 (TBST). Membranes were probed with
an anti-mouse IgG kappa, HRP-linked secondary antibody (1:1000 in TBS containing 3% non-fat milk, Santa
Cruz Biotechnology, TX, USA) for 1 h at room temperature followed by washing with TBST. Enhanced chemiluminescent (ECL) substrate reagent (Thermo Fisher
Scientific, MA, USA) was used for secondary antibody
detection and chemiluminescence was imaged using the
Azure C500 gel imager (Azure Biosystems, CA, USA).
Membranes were probed with an anti-β-actin antibody
(1:1000 in TBS containing 3% non-fat milk, Santa Cruz
Biotechnology, TX, USA) as a loading control, and membranes were incubated in the secondary antibody and
ECL substrate as described above. NIH ImageJ (version
1.53e, MD, USA) was used to quantify the intensity of the
Western blot bands and all the values were normalized to
PS19-Saline mice.
Pharmacokinetic (PK) study

All animal procedures were approved by the University of
La Verne and Pomona College Institutional Animal Care
and Use Committee. Eight-week-old male C57BL/6J mice
(24 − 27 g) were obtained from the Jackson Laboratories
(ME, USA). Mice had constant access to food and water
and were maintained on a 12 h light/12 h dark cycle, and
mice were randomly assigned to treatment groups. For
the single-dose PK study, TfRMAb-TNFR fusion protein
(1.75 mg/kg) or etanercept (0.875 mg/kg) were injected
via the IP route in the volume of 130 − 140 μL per mouse.
Each treatment group comprised 4 − 6 mice. Blood was
collected in sodium citrate (9 parts blood and 1-part
sodium citrate) at 3, 6, 20, and 24 h following IP administration, and plasma was collected.
For chronic dosing PK study, male heterozygous APP/
PS1 mutant mice (strain B6C3-Tg APPswe, PSEN1dE9,
85Dbo/Mmjax, stock 004462, Jackson Laboratories,
ME, USA) (~ 19 months of age) were injected IP three
days per week for four weeks with either 1.75 mg/
kg TfRMAb-TNFR (n = 4) or an equivalent volume of
saline (n = 6). One week after 4-week dosing, all mice
that were chronically treated with saline or TfRMAbTNFR received a final single 1.75 mg/kg dose of the
TfRMAb-TNFR fusion protein via the IP route to determine the impact of chronic TfRMAb-TNFR dosing on
plasma PK. Blood was collected at 3, 6, and 24 h after
the final injection for plasma collection. For the single and chronic PK studies, plasma TfRMAb-TNFR
or etanercept concentrations were determined using a
TNFR sandwich ELISA described below. Plasma concentration–time profiles were used to perform noncompartmental analysis to determine PK parameters
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(maximum plasma concentration (Cmax) and area under
the plasma concentration − time curve (AUC)) using
Thermo Scientific Kinetica 5.0 (Thermo Fisher Scientific, MA, USA), as described previously [47–49].
TNFR ELISA

TfRMAb-TNFR fusion protein binding to TNF-α
(Additional file 2: Fig. S1B), and TfRMAb-TNFR and
etanercept plasma concentrations were quantified by a
sandwich ELISA. The human TNF-α (hTNF-α) (PeproTech, Rocky Hill, NJ, USA) was the capture agent and
2 µg/mL of hTNF-α was plated in 96-well plates, and
incubated overnight at 4 ºC. The wells were blocked
with TBS containing 1% bovine serum albumin (TBSB)
(0.01 M Tris/0.15 M NaCl/1% BSA/pH7.4) for 30 min
at room temperature. Plasma samples (diluted 1:10 in
TBSB) were added to the wells and incubated for 1 h
at room temperature followed by washing with TBST.
Alkaline phosphatase-conjugated detector agents, goat
anti-human IgG-Fc fragment antibody (Bethyl, TX,
USA) that binds to the human Fc domain of etanercept and goat anti-mouse light chain (kappa) antibody
(Bethyl Laboratories, Inc., TX, USA) that binds to the
TfRMAb domain of the TfRMAb-TNFR, were added to
the wells for 1 h at room temperature followed by washing with TBST. Wells were then incubated with P-nitrophenyl phosphate solution (Sigma Aldrich, St. Louis,
MO, USA) for 15 min in the dark at room temperature
and the reaction was stopped by adding 1.2 M NaOH.
Blank corrected absorbance measured at 405 nm was
used to calculate plasma concentrations using a standard curve.
Statistical analysis

All numerical variables are represented as mean ± SEM,
and all statistical analysis was performed using GraphPad Prism 8 (GraphPad Software Inc., CA, USA) and as
described by others [50]. Outliers were identified using
the Grubb’s test. Independent two-sample t-test or
one-way ANOVA with Holm–Sidak’s post hoc test was
used to compare the means of two or more than two
groups, respectively. To test the effects of two factors
(e.g., treatment groups and time, or treatment groups
and brain region), two-way repeated-measures ANOVA
with Holm–Sidak’s multiple comparisons test was used.
Open-field data were analyzed using two-way ANOVA
with Holm–Sidak’s multiple comparisons test. Correlations between two numerical variables were analyzed
by the Pearson correlation. A two-tailed p < 0.05 was
considered statistically significant.
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Results
Effect of biologic TNF‑α inhibitors on pTau (Ser202, Thr205)
in the PS19 mice

To determine the impact of TNF-α inhibitors on tau
pathology, we quantified the pTau-positive area in the
cortex, hippocampus, entorhinal cortex, and amygdala using the AT8 antibody. We then determined
the overall AT8-positive area (average of the regional
AT8-positive area). As expected, the overall AT8-positive area was significantly lower in the WT mice compared to the PS19-Saline controls, in both male (93%
lower; p < 0.001) and female (78% lower; p < 0.01) mice
(Fig. 1B–D; Additional file 3: Fig. S2A). Etanercept significantly reduced the overall AT8-positive area in both
male and female PS19 mice by 73% (p < 0.01) and 58%
(p < 0.05), respectively (Fig. 1B–D; Additional file 3: Fig.
S2A). While TfRMAb-TNFR resulted in a 61% decrease
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(p < 0.05) in the overall AT8-positive area in the female
PS19 mice (Fig. 1C–D; Additional file 3: Fig. S2A), surprisingly there was no change in the AT8-positive area
in the TfRMAb-TNFR-treated male PS19 mice compared to the PS19-Saline mice (Fig. 1B, D; Additional
file 3: Fig. S2A).
Effect of the biologic TNF‑α inhibitors on microgliosis
in the PS19 mice

Microgliosis was assessed in the cortex, hippocampus,
entorhinal cortex, and amygdala by measuring the brain
tissue area positive for the microglial marker, Iba-1. The
overall Iba-1-positive area, which is the average of the
regional Iba-1-positive areas, was significantly lower
in the WT mice compared with the PS19-Saline controls in both male (35% lower; p < 0.01) and female (18%
lower; p < 0.05) mice (Fig. 2A–C; Additional file 4: Fig.

Fig. 2 Effect of TNF-α inhibitors on microgliosis in the PS19 mice. Iba-1-positive area in different brain regions in male (A) and female (B) mice.
The overall Iba-1-positive area, which is an average of the regional Iba-1-positive area was significantly reduced by etanercept in both sexes and
by TfRMAb-TNFR in female mice (A, B). Representative images of Iba-1-positive microglia in the amygdala (black boxed region representing the
piriform-amygdalar region in the thumbnail brain section image) and the hippocampus (red boxed region in the thumbnail brain section image)
of the PS19 mice (C). Scale bar = 50 μm and thumbnail image in C was taken from the Allen Institute. Scatter plot showing a strong positive
correlation between the overall AT8-positive area (%) and the overall Iba-1-positive area (%) in males and female mice combined (D; Pearson
r = 0.68, p < 0.0001). Data are presented as mean ± SEM of 10–12 mice per treatment group (5–7 per sex per group). Two-way ANOVA with repeated
measures with Holm–Sidak’s post hoc test was used to compare to PS19-Saline controls. *p < 0.05, **p < 0.01, ****p < 0.0001
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S3). TfRMAb-TNFR treatment significantly (p < 0.05)
reduced the Iba-1-positive area by 18% in the female
PS19 mice compared to PS19-Saline controls (Fig. 2B–
C; Additional file 4: Fig. S3). No significant change in
the Iba-1-positive area was observed in the TfRMAbTNFR-treated male PS19 mice (Fig. 2A–C; Additional file 4: Fig. S3). Etanercept significantly (p < 0.05)
decreased the Iba-1-positive area in both male (24%
decrease) and female (23% decrease) mice compared
to sex-matched PS19-Saline controls (Fig. 2A–C; Additional file 4: Fig. S3). A strong significant positive correlation was observed in the overall AT8-positive
and overall Iba-1-positive area in the current study
(Pearson r = 0.68, p < 0.0001; Fig. 2D). To determine
if the reduction in the Iba-1-positive area was due to
a reduction in microglia number or size, we quantified
the number of microglia and estimated the microglial
soma size. We found a significant increase (p < 0.01) in
the total number of microglia in the PS19-TfRMAbTNFR male mice compared to the PS19-Saline male
mice (Additional file 5: Fig. S4A), but no difference
in the total number of microglia in the female mice
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(Additional file 5: Fig. S4B). With respect to the soma
size, the number of microglia with a smaller soma size
(< 50-pixel units) was also significantly higher (p < 0.01)
in the PS19-TfRMAb-TNFR male mice compared to
the PS19-Saline male mice (Additional file 5: Fig. S4C).
The number of microglia with a larger soma (> 50-pixel
units) was significantly higher (p < 0.0001) in the PS19
male mice compared to the WT male mice (Additional
file 5: Fig. S4E). Etanercept (p < 0.0001) and TfRMAbTNFR (p < 0.01) treatment significantly reduced the
number of microglia with a larger soma in the male
PS19 mice (Additional file 5: Fig. S4E). On the other
hand, there was a significant reduction in the number of microglia with smaller soma size in the WTSaline (p < 0.001), PS19-TfRMAb-TNFR (p < 0.001) and
PS19-Etanercept (p < 0.01) female mice compared with
PS19-Saline female mice (Additional file 5: Fig. S4D).
The number of microglia with a larger soma size was
unchanged in the female mice (Additional file 5: Fig.
S4F).

Fig. 3 Effect of TNF-α inhibitors on neuronal health. Representative images of H&E-stained hippocampal granule cell layer of the dentate gyrus
(DG) in the PS19 mice (A). Scale bar = 200 μm. The thumbnail images showing the DG regions that were imaged are taken and adapted from
the Allen Institute. The DG granule cell layer area, as measured using ImageJ, was significantly greater in the WT-Saline, PS19-TfRMAb-TNFR, and
PS19-Etanercept mice compared to PS19-Saline controls (B). Scatter plot showing that AT8-positive area (%) was negatively correlated with the
total hippocampal neuronal cell area (C; Pearson r = -0.42, p < 0.05). PSD95 (synaptic/neuronal health marker) protein level in the whole-brain
homogenates detected by Western blotting was significantly increased in the PS19-TfRMAb-TNFR and PS19-Etanercept mice compared to
PS19-Saline controls (D). Data are presented as mean ± SEM of 6–11 mice per treatment group (3–7 per sex per group). For H&E staining, n = 6 mice
per treatment group. For the PSD95 Western, n = 7–11 mice per treatment group. Male and female mice were combined due to a lack of sex-related
effects. One-way ANOVA with Holm–Sidak’s post hoc test was used to compare to PS19-Saline controls. *p < 0.05, ***p < 0.001, and ****p < 0.0001
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Effect of the biologic TNF‑α inhibitors on neuronal health
in the PS19 mice

The area occupied by the hippocampal granule cell layer
of the DG was significantly smaller (p < 0.001) in the
PS19-saline mice compared with the WT mice (Fig. 3A,
B). The loss of the DG granule cell layer in the PS19 mice
was significantly attenuated (p < 0.05) by both etanercept and TfRMAb-TNFR treatment (Fig. 3A, B). No
significant difference was observed in the hippocampal
pyramidal cell layer area of the CA1-3 regions between
the experimental groups (data not shown). A small but
significant negative correlation was observed in the overall AT8-positive and the total hippocampal neuronal
cell area (Pearson r = − 0.42, p < 0.05; Fig. 3C). The protein levels of the post-synaptic marker, PSD95 (a marker
of synaptic health), in whole-brain homogenates, were
not significantly reduced in the PS19-Saline controls
(Fig. 3D). However, TfRMAb-TNFR and etanercept treatment led to a significant increase in the protein levels of
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PSD95 in the whole-brain homogenates of PS19 mice
(Fig. 3D).
Effect of TNF‑α inhibitors on locomotion hyperactivity

The male PS19-Saline controls traveled a greater distance (p < 0.05) (Fig. 4A, C) and had a higher mean speed
(p < 0.05) (Fig. 4B, C) compared to the WT male mice.
Interestingly, this increase in distance traveled and mean
speed was normalized by chronic etanercept treatment in
the PS19 male mice, but not by chronic treatment with
TfRMAb-TNFR (Fig. 4A–C). Neither the genotype nor
the treatment affected locomotion hyperactivity in the
female mice (Fig. 4A–C). A strong significant positive
correlation was observed in the overall AT8-positive area
in the brain and distance traveled in the male mice (Pearson r = 0.71, p < 0.001; Fig. 4D). No significant difference
was observed in the time spent in the center, an indicator
of anxiety-like behavior, between any experimental group
in the current study (data not shown).

Fig. 4 Effect of TNF-α inhibitors on locomotion. Significantly elevated locomotion indices, including distance travelled (A) and mean speed
(B), in the PS19 male mice compared to the WT male mice. Chronic etanercept treatment attenuated these changes in locomotion in the PS19
male mice. Chronic TfRMAb-TNFR treatment did not have any effect on locomotion in the male mice. No significant difference was observed in
locomotion between any experimental groups in the female mice. Representative trajectory maps are shown in C. Distance travelled and overall
brain AT8-positive area showed a strong significant positive correlation in the male mice (D; Pearson r = 0.71, p < 0.001). Two-way ANOVA with Holm
Sidak’s post hoc test was used to compare with PS19-Saline (n = 5–7 mice per group per sex) in A and B. *p < 0.05 compared to PS19-Saline controls
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Fig. 5 Plasma pharmacokinetic (PK) profile. Experimental design (top panel) and plasma concentration–time curves (bottom panel) following a
single IP 1.75 mg/kg dose of TfRMAb-TNFR or IP 0.875 mg/kg dose of etanercept in C57BL/6 J mice (A). Experimental design (top panel) and plasma
concentration–time curves (bottom panel) following chronic TfRMAb-TNFR dosing (B). Schematics in A and B were prepared using BioRender.com.
For chronic TfRMAb-TNFR treatment, APP/PS1 mice were treated with a single 1.75 mg/kg IP injection after chronic 4-week treatment with saline
(single injection group) or 1.75 mg/kg TfRMAb-TNFR (chronic injection group) and plasma samples were collected at 3 h, 6 h and 24 h following
injection (B). Data are shown as the mean ± SEM of n = 4–6 mice per treatment group per time point

Table 1 Plasma pharmacokinetic (PK) parameters following a single IP injection of 1.75 mg/kg TfRMAb-TNFR or 0.875 mg/kg
etanercept, and following chronic IP injection of 1.75 mg/kg TfRMAb-TNFR (a single 1.75 mg/kg TfRMAb-TNFR injection after chronic
4-week treatment with saline or 1.75 mg/kg TfRMAb-TNFR)
Route

Group

Dose

Dosing frequency

mg/kg

AUC(0–24 h)

Cmax

AUC(0–∞)

µg min/mL

µg/mL

µg min/mL

Single injection PK
IP

TfRMAb-TNFR

1.75

Etanercept

0.875

Once

864 ± 46

7947 ± 664****

Chronic dosing PK
TfRMAb-TNFR (single injection)

1.75

Once at the end of 4 weeks

TfRMAb-TNFR (chronic injection)

1.75

3 days per week for 4 weeks

1705 ± 157

2352 ± 280

1.6 ± 0.08

10.2 ± 1.3***
1.8 ± 0.3

2.4 ± 0.2

875 ± 45

11,056 ± 843****
6114 ± 1268

6960 ± 2033

Data are shown as the mean ± SEM (n = 4–6 mice per treatment group per time point). Two-sample t test was used to compare PK parameters

***p < 0.001, ****p < 0.0001 compared to TfRMAb-TNFR for the single injection PK study.

Plasma PK after IP administration of biologic TNF‑α
inhibitors in mice

The plasma concentrations following a single IP administration of 1.75 mg/kg TfRMAb-TNFR or 0.875 mg/kg
etanercept are shown in Fig. 5A, and plasma PK parameters are summarized in Table 1. The plasma Cmax was
1.6 ± 0.08 µg/mL for the TfRMAb-TNFR fusion protein.
The plasma C
 max following an equimolar dose of etanercept was fivefold higher (p < 0.001) at 10.2 ± 1.3 µg/
mL (Fig. 5A; Table 1). Accordingly, the plasma AUC
over 24 h was eightfold higher (p < 0.001) for etanercept
(7947 ± 664 µg•min/mL) compared to the TfRMAbTNFR fusion protein (864 ± 46 µg min/mL) (Table 1).
To study the impact of chronic TfRMAb-TNFR dosing
on plasma concentrations of the fusion protein, following 4-week chronic treatment with the TfRMAb-TNFR
or saline, mice received a single 1.75 mg/kg IP injection

of TfRMAb-TNFR and plasma samples were collected
at 3 h, 6 h, and 24 h following injection. No significant
differences were observed in the plasma PK parameters between the 4-week saline-treated mice receiving
a single dose of 1.75 mg/kg TfRMAb-TNFR and 4-week
TfRMAb-TNFR-treated mice receiving a single dose of
the TfRMAb-TNFR (Fig. 5B; Table 1). The Cmax values
were comparable between the groups at 1.8 ± 0.3 µg/mL
and 2.4 ± 0.2 µg/mL for the 4-week saline-treated mice
receiving a single 1.75 mg/kg dose of TfRMAb-TNFR
and 4-week TfRMAb-TNFR-treated mice receiving a
single 1.75 mg/kg dose of TfRMAb-TNFR, respectively
(Table 1). Similarly, the plasma AUC over 24 h was comparable between the two groups at 2352 ± 280 µg min/mL
and 1705 ± 157 µg•min/mL for the 4-week saline-treated
mice receiving a single 1.75 mg/kg dose of TfRMAbTNFR and 4-week TfRMAb-TNFR-treated mice
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receiving a single 1.75 mg/kg dose of TfRMAb-TNFR,
respectively (Table 1). It should be noted that the plasma
concentrations of TfRMAb-TNFR following a single
injection in Fig. 5A (blue curve) and Fig. 5B (blue curve)
show differences that may be attributed to the different
age and genotype of the mice used in Fig. 5A (8-week-old
C57BL/6J) and Fig. 5B (19-month-old APP/PS1), but not
to chronic saline dosing in Fig. 5B based on our previous
work [44]. For this reason, the plasma concentrations following single and chronic TfRMAb-TNFR dosing were
compared in two separate groups of 19-month-old APP/
PS1 (in Fig. 5B; blue and orange curves). The single injection data presented in Fig. 5A (blue curve) was not compared with Fig. 5B (blue curve).
Hematological profile

The hematologic profiles following a single 1.75 mg/
kg TfRMAb-TNFR IP injection in C57BL/6 J mice and
chronic 8-week treatment with 1.75 mg/kg TfRMAbTNFR or 0.875 mg/kg etanercept in the PS19 mice are
shown in Fig. 6A, B, respectively. A single injection of
1.75 mg/kg TfRMAb-TNFR induced a significant 92%
reduction (p < 0.001) in reticulocyte counts compared
to saline controls (Fig. 6A), while the other hematologic
parameters remained unchanged (Fig. 6A). Interestingly, the suppression of reticulocyte count following
a single injection normalized after chronic treatment
with 1.75 mg/kg TfRMAb-TNFR for 8 weeks (Fig. 6B).
Chronic treatment of TfRMAb-TNFR did not result in
significant changes in other hematological parameters
compared to PS19-Saline controls (Fig. 6B). Chronic
8-week treatment with 0.875 mg/kg of etanercept led to
a significant 58% increase (p < 0.01) in the platelet counts
compared to PS19-Saline controls, and no change in any
other hematological parameter was observed (Fig. 6B).
All the mice survived the duration of the study and compared to the baseline body weights, no significant change
in the body weights of mice was observed throughout the
study for any experimental group (Fig. 6C).

Discussion
The results of the current study show that both the BBBpenetrating biologic TNF-α inhibitor (TfRMAb-TNFR)
and the non-BBB-penetrating biologic TNF-α inhibitor (etanercept) exert protective effects in the female
PS19 mice, with differential therapeutic effects in male
PS19 mice. First, we show that etanercept significantly
reduced pTau (ser202 and thr205) in both the male and
female PS19 mice, and TfRMAb-TNFR reduced pTau in
female PS19 mice. Second, pTau was significantly correlated with microgliosis, and etanercept significantly
reduced microgliosis in both male and female PS19
mice. TfRMAb-TNFR reduced microgliosis in the female
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PS19 mice. Third, both TfRMAb-TNFR and etanercept improved neuronal health. Fourth, the locomotion
hyperactivity of the PS19 male mice was attenuated with
chronic etanercept treatment. Fifth, equimolar dosing of
TfRMAb-TNFR and etanercept resulted in significantly
different plasma concentrations, which may explain the
differential therapeutic effects of these biologic TNF-α
inhibitors in male mice. Finally, chronic 8-week treatment with these biologic TNF-α inhibitors had no major
impact on the hematologic parameters of the PS19 mice.
The link between microglial activation-mediated neuroinflammation and tau pathology in AD and other
tauopathies has been extensively studied [51, 52]. Accumulating research in this area postulates that microglial
activation is an early event in tauopathies that precedes
tau phosphorylation and tangle formation, eventually
causing neuronal cell death and neurodegeneration [53,
54]. An important event in this cascade of microgliamediated abnormal tau lesion accumulation is the release
of cytokines that directly augment tau phosphorylation
and the formation of tau tangles both in vivo and in vitro.
For example, direct application of IL-1β or IL-6 to neuronal and microglial cultures increased tau phosphorylation and neuronal loss [55, 56]. Similarly, sustained brain
levels of IL-1β and TNF-α increased tau phosphorylation and neuronal cell death in vivo [15, 57]. Accordingly,
CNS TNF-α inhibition with the intracerebroventricular
injection of a TNF-α antibody, and peripheral TNF-α
modulation significantly reduced tau phosphorylation in
a mouse models of amyloidosis [22, 58].
Consistent with these findings, we found a significant
reduction in the AT8-positive immunoreactive area,
which measures pTau at sites ser202 and thr205, with
chronic treatment with both the biologic TNF-α inhibitors. We also observed sex differences in the efficacy of
the two biologic TNF-α inhibitors in the current study.
The BBB-penetrating TfRMAb-TNFR significantly
reduced pTau in the female PS19 mice; interestingly,
etanercept, which is shown not to cross the BBB [28],
reduced pTau in both the male and female PS19 mice
(Fig. 1; Additional file 3: Fig. S2). No change in total
tau levels in the plasma and whole-brain homogenates
was observed between the PS19-Saline and the biologic
TNF-α inhibitor-treated PS19 mice (Additional file 3:
Fig. S2). Further, the reduction in tau phosphorylation
with the biologic TNF-α inhibitors paralleled the reduction in microgliosis in the current study, and the AT8positive area showed a strong positive correlation with
the Iba-1-positive area (Fig. 2). A recent report showed
similar results wherein blockage of microglial proliferation with JNJ-40346527, a brain-permeant CSF1R
inhibitor, reduced TNF-α and tau pathology in the spinal cords of the PS19 mice [59]. Together, these mouse
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Fig. 6 Complete blood count (CBC). A CBC was performed following a single 1.75 mg/kg TfRMAb-TNFR IP injection in male C57BL/6J mice (A)
or chronic 8-week treatment with saline, 1.75 mg/kg TfRMAb-TNFR or 0.875 mg/kg etanercept in the male and female PS19 mice (B). For CBC
analysis, red blood cell (RBC, i), hematocrit (Hct, ii), hemoglobin (HGB, iii), reticulocytes (iv), mean corpuscular volume (MCV, v), platelets (vi), and
white blood cells (WBC) (B, viii) were measured. WBC counts were not measured following the single injection study. Sexes were combined for
chronic CBC data due to no sex-related effects. The body weights of age-matched WT-Saline and PS19 mice were measured weekly. No significant
difference was observed between the baseline and terminal body weights of the mice in any experimental group (C). For CBC data following a
single injection (A), the two-sample t test was used to compare to the WT-Saline mice (n = 3 mice per group). Two-way repeated-measures ANOVA
with Holm–Sidak’s post hoc test was used for CBC data after 8-week treatment to compare to PS19-Saline mice (n = 4–6 mice per group) (B) and
body weight changes (n = 5–7 mice per group) (C). **p < 0.01, ****p < 0.0001

studies reinforce the association between pTau lesions
and microglial activation seen in human AD brains [51,
60] and in rodent models, including the PS19 mouse
model used in the current study [31, 61].

One key characteristic of microglia is an activationinduced change in their morphology [62–64]. Under
physiological conditions, microglia are said to be in
a resting/quiescent/surveilling state that is typically
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characterized morphologically by the presence of highly
ramified microglia with a small soma. However, once
activated, the microglia transition into an amoeboid
shape with an enlarged soma [62, 63], and soma size is a
significant correlate of microgliosis [65]. Accordingly, the
number of microglia with a larger soma size was significantly higher in the PS19 male mice compared to the WT
mice suggesting the presence of more activated microglia in the PS19 male mice. The impact of the biologic
TNF-α inhibitors on the microglial morphology varied by
sex and the inhibitor. For example, the lack of change in
microgliosis by TfRMAb-TNFR in the male mice (Fig. 2)
appears to be driven by an increase in the number of
microglia with a smaller soma size and an accompanying
decrease in the number of microglia with a larger soma
size (Additional file 5: Fig. S4). However, the reduction
in microgliosis by etanercept appears to be driven by a
reduction in the microglia with a larger soma size. In the
female mice, the reduction in microgliosis appears to be
driven by the reduction in the microglia with a smaller
soma size rather than microglia with a larger soma size
(Additional file 5: Fig. S4). Overall, our results suggest that the effect of the biologic TNF-α inhibitors on
microgliosis is largely modulated by changes in microglia
morphology rather than by changes in total microglia
number. Future work using different markers for homeostatic (e.g., P2ry12) versus disease-associated (e.g., Axl,
Apoe4) microglia will help elucidate the specific microglial phenotype modulated by the biologic TNF-α inhibitors [66].
Abnormal tau lesions correlate with neuronal loss and
cognitive decline in AD [67], and a recent study showed
that both tau and microglial activation can predict cognitive decline in AD [68]. In line with this, we wanted to
determine if the attenuation in the pTau and microglial
activation with the TNF-α inhibitors is associated with
improvement or preservation of neuronal health. The
PS19 mice exhibited a significant hippocampal neuronal
loss in the DG, and we found a small but significant negative correlation between the AT8-positive area and hippocampal neuronal cell area in the PS19 mice (Fig. 3).
These findings are consistent with the progressive hippocampal neuronal loss seen in the PS19 mouse model
between 6- to 12-months of age [31]. We also measured
the levels of PSD95, a post-synaptic protein that is widely
used as a marker of synaptic health and is known to be
modulated by TNF-α [69]. Notably, both the TfRMAbTNFR and etanercept improved hippocampal and wholebrain tissue neuronal health in the current study (Fig. 3).
PS19 mice exhibit a hyperactive phenotype which
is a characteristic of AD patients [39, 40]. Consistent
with previous work with the PS19 mice [39], we found
increased locomotion hyperactivity in the PS19 male
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mice (Fig. 4). Interestingly, the locomotion hyperactivity
was associated with increased pTau lesions in the male
mice in the current study, showing a direct relationship
between these parameters in these mice. Locomotor
hyperactivity was attenuated by chronic etanercept treatment but not TfRMAb-TNFR treatment, paralleling the
reduction in AT8-positive tau lesions with these TNF-α
inhibitors in the male mice. Though the PS19 mice display a hyperactive phenotype, these mice may also display deficits in hippocampal-dependent learning [39–41],
and future work will investigate the effects of the biologic
TNF-α inhibitors using different hippocampal-dependent memory testing paradigms.
Both TfRMAb-TNFR and etanercept can modulate
peripheral TNF-α following systemic administration,
while only the TfRMAb-TNFR can enter the brain to
exert direct CNS anti-TNF-α effects [36]. Using radiolabeled TfRMAb-TNFR in mice, we have previously
shown that a single IP injection of TfRMAb-TNFR for
doses between 1–3 mg/kg results in a brain concentration
of ~ 0.5% injected dose/gram brain at 24 h after injection
[35]. Based on this, the predicted brain concentration
of TfRMAb-TNFR following a single 1.75 mg/kg dose is
0.3 µg/g brain (2 nM) at 24 h following a single IP injection, assuming a 30 g mouse. The brain uptake of etanercept, on the other hand, is reported to be 20- to 13-fold
lower than that of the brain-penetrating TNF-α inhibitor;
furthermore, etanercept is found to distribute only to the
brain blood volume, and not enter the brain parenchyma
[28]. An alternate route for etanercept entry into the
brain is via an impaired BBB in the PS19 mice. However,
we did not observe changes in BBB tight junction proteins (ZO-1 and claudin-5) in the PS19 mice compared
to the WT mice (Additional file 6: Fig. S5) consistent with
previous work showing no change in BBB permeability in
8–10-month-old PS19 mice [70]. We measured TNF-α
levels in the plasma and whole-brain homogenates using
ELISA and Western blotting, respectively, but we did not
see any significant change with the biologic TNF-α inhibitor treatment (Additional file 7: Fig. S6). However, we did
see an increase in the whole-brain protein levels of IĸBα,
which is degraded following TNF-α stimulation [71] and
is therefore expected to increase after TNF-α inhibition,
with TfRMAb-TNFR treatment (p < 0.01), and a similar
trend was observed with etanercept treatment (p = 0.08;
Additional file 7: Fig. S6). Taken together, the reduction
in pTau, microgliosis, and improvement in neuronal
health with both the TfRMAb-TNFR and etanercept in
the current study indicates that these protective effects
are modulated by peripheral, rather than direct CNS
effects of these inhibitors in the PS19 mice. These findings are in agreement with recent reports showing that
peripheral TNF-α alone can modulate microgliosis,
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neuronal health, and Aβ-dependent AD pathology in the
5xFAD mice [19, 20]. Accordingly, inhibition of peripheral TNF-α and modulation of the innate immune system
were shown to reduce Aβ-associated tau-phosphorylation in the 3xTg mouse model [58].
Despite the ability of both TfRMAb-TNFR and etanercept to modulate peripheral TNF-α, we observed a significant difference in their therapeutic effects in the male
PS19 mice. To elucidate the possible reason behind this
difference in the male mice, we studied the plasma pharmacokinetics of these two inhibitors when given at equimolar doses to male mice. Furthermore, previous work
with TfRMAb-based fusion proteins shows no difference
in plasma pharmacokinetics between male and female
mice [72]. Similarly, etanercept pharmacokinetics show
only minor insignificant differences between males and
females and were reported to remain largely consistent
between sexes [73, 74]. Therefore, female mice were not
used for plasma pharmacokinetic studies.
Etanercept is 50% TNFR and TfRMAb-TNFR is 25%
TNFR based on amino acid sequence [36, 38]. As a result,
the dose of etanercept was half that of TfRMAb-TNFR
in the current study. However, despite equimolar dosing, the plasma Cmax was > 500% higher and the plasma
AUC was > 800% higher for etanercept compared to the
TfRMAb-TNFR fusion protein after a single IP dose over
24 h (Fig. 5; Table 1). Plasma concentrations of TfRMAbbased therapeutics may be further altered following
chronic dosing. For example, our recent work reported
a significant increase in plasma clearance, and thereby
a significant decrease in the plasma concentrations of
TfRMAb (not fused to a therapeutic partner), following
repeated administrations [47]. On the contrary, when the
TfRMAb was fused to glial-derived neurotrophic factor
(GDNF), no change in plasma clearance or concentrations of the TfRMAb-GDNF fusion protein was observed
following chronic repeated dosing [72]. Based on this,
we hypothesized that the plasma PK of TfRMAb-based
fusion proteins is highly regulated by the fusion partner
[47]. To determine the impact of chronic TfRMAb-TNFR
dosing on plasma PK which may potentially impact the
therapeutic efficacy of the fusion protein, we determined plasma concentrations of the fusion protein after
repeated dosing. We found no change in the plasma concentrations of TfRMAb-TNFR following repeated dosing (Fig. 5; Table 1). Overall, the TfRMAb-TNFR fusion
protein had a lower plasma concentration than etanercept, which is attributed to the TfR-mediated peripheral
clearance of the TfRMAb-TNFR fusion protein from the
circulation. The pTau load was 63% higher in the male
mice compared to the female PS19 mice (Fig. 1), and it
is conceivable that the higher pTau load seen in the male
PS19 mice requires higher sustained plasma exposure
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of the TNF-α inhibitor, or a higher dose to produce a
therapeutic effect. The low plasma exposure of TfRMAbTNFR and the higher pTau load in the male PS19 mice
may explain the lack of an effect of the TfRMAb-TNFR
on pTau and microgliosis in the male PS19 mice in the
current study. Notably, our previous work comparing the
TfRMAb-TNFR and etanercept at a twofold higher dose
(3 mg/kg) showed more robust effects of the TfRMAbTNFR than etanercept in the male APP/PS1 mouse
model of amyloidosis [42].
TfRMAb-based fusion proteins are associated with
acute TfRMAb-mediated reticulocyte suppression,
and TNF-α inhibitors including etanercept are potent
immune modulators that can cause leukopenia and
increase the risk of infections [47, 75, 76]. Accordingly,
we found a significant reduction in reticulocytes with
a single dose of the TfRMAb-TNFR, a TfRMAb-based
therapy (Fig. 6). However, this suppression was acute and
no reduction in reticulocytes or any other hematologic
parameter was observed following 8-week chronic dosing
of the TfRMAb-TNFR fusion protein. This is consistent
with previous reports showing that reticulocyte suppression is short-lived and acute after administration of
TfRMAb-based fusion proteins [44, 47, 75]. Mice treated
with etanercept, on the other hand, had significantly elevated platelet counts following chronic dosing, which has
been previously reported with etanercept use [77], with
no other change in the hematologic parameters. Further,
no change in weight along with a largely stable hematologic profile showed that chronic treatment with the biologic TNF-α inhibitors was safe in the PS19 mice [78].
The current study has some limitations. First, the
absence of thioflavin-S-positive tau tangles (data not
shown) in the brains of the 8-month-old PS19 mice in
the current study precluded our ability to explore the
effect of the biologic TNF-α inhibitors on tau aggregates.
Second, we did not study the impact of these biologic
TNF-α inhibitors on tau pathology and microgliosis in
the locus coeruleus (LC), which is one of the first brain
structures to develop tau pathology and is implicated in
tau spreading [79]. A previous study showed accumulation of tau tangles in the LC of PS19 mice, a process that
is highly variable and dependent on the motor deficits in
these mice [79], and future work will be needed to elucidate the effects of these biologic TNF-α inhibitors on
tau pathology and microgliosis in the LC. Third, we have
only studied the effect of the TNF-α inhibitors on tau
phosphorylated at ser202 and thr205; the effect on tau
phosphorylation at other sites was not studied. Fourth,
we used whole-brain homogenates to study the levels of
PSD95, and we did not see a reduction in PSD95 levels in
PS19 mice compared to WT mice. Since the hippocampus is the primary site of neuronal loss in the PS19 mice
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[31], the absence of a significant difference in the postsynaptic marker PSD95 between the PS19 and WT mice
may be attributed to the use of whole-brain homogenate
preparations in the current study rather than hippocampal brain homogenates to measure PSD95. Further, our
data showing a reduction in microgliosis and pTau does
not show causation. Whether the reduction in pTau
reduces microgliosis or a reduction in microgliosis drives
the reduction in pTau, is unclear. A recent study showed
that amyloid potentiates microgliosis, which in turn
drives tau pathology in the human AD brains [80]. Future
work looking at the effects of these biologic TNF-α inhibitors in mouse models that combine both amyloid and
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tau pathology, along with the use of CSF1R inhibitors
to deplete microglia, will allow us to elucidate the role
of microglia-derived TNF-α in the protective effects of
these biologic TNF-α inhibitors on both amyloid and tau
pathology.

Conclusion
Overall, the data presented in this in vivo study in
the PS19 mouse model of tauopathy are the first to
report significant therapeutic effects of biologic TNF-α
inhibitors on Aβ-independent tau pathology following systemic administration (Fig. 7). Our results show
that both the BBB-penetrating TfRMAb-TNFR and

Fig. 7 Systemic administration of etanercept (a non-BBB-penetrating TNF-α inhibitor) and TfRMAb-TNFR (a BBB-penetrating TNF-α inhibitor) results
in a reduction in phosphorylated tau and microgliosis, and improvement in neuronal health in the PS19 mouse model of tauopathy. Etanercept
treatment also reduces hyperactivity in the PS19 mice. These results support the development of biologic TNF-α inhibitors for tauopathies,
including AD. Figure was prepared using BioRender.com
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non-BBB-penetrating TNF-α inhibitor modulate the
microglia-tau-neurodegeneration axis, suggesting the
involvement of peripheral TNF-α in these processes.
Future work replicating these findings in other models
of tauopathies and models combining Aβ and tau pathology may yield important preclinical data supporting
the use of biologic TNF-α inhibitors for AD and other
tauopathies.
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Additional file 1: Supplementary methods.
Additional file 2: Fig. S1 High-affinity binding of the TfRMAb-TNFR to
the TfR (A) and TNF-α (B). iPSC-derived brain endothelial cells (ihBMECs)
cultured in Transwell inserts were treated with 1 µg/mL TNF-α and 7 µg/
mL TfRMAb-TNFR for up to 3 days. TNF-α reduced TEER (C) and increased
sodium fluorescein passage across the brain endothelial monolayer (D).
These effects were normalized by TfRMAb-TNFR treatment. All the experiments were repeated three times independently and data were expressed
as mean ± SEM. Two-way repeated-measures ANOVA or one-way ANOVA
with Holm Sidak’s post hoc test was used in C and D, respectively. *p<0.05,
***p<0.001, ****p<0.0001. OD: optical density.
Additional file 3: Fig. S2. Representative AT8-stained images of the
cortex and entorhinal cortex. Images were acquired at 40X. Scale bar =
30 µm (A). No significant change in the plasma (B) and brain total tau
levels was detected using ELISA (C). A heat map showing the correlation between plasma total tau, brain total tau and overall AT8-positive
area (%) in male and female mice combined (D). Total tau in plasma and
brain shared a strong positive correlation (Pearson r = 0.76, p<0.0001).
AT8-positive area showed a modest positive correlation with total tau in
the plasma (Pearson r = 0.43, p<0.01) and brain (Pearson r = 0.46, p<0.05).
Data are presented as mean ± SEM of n = 6-11 mice per treatment
group in B and C. Male and female mice were combined due to a lack of
sex-related effects. One-way ANOVA with Holm–Sidak’s post hoc test was
used to compare to PS19-Saline controls in B and C. Pearson correlation
was used for correlation analysis in D.
Additional file 4: Fig. S3. Representative Iba-1-stained images of the
cortex and entorhinal cortex. Images were acquired at 10X with a digital
3X zoom. Scale bar = 25 µm.

Additional file 5: Fig. S4. Data from male mice are shown in A, C and E,
and data from female mice are shown in B, D and F. A significantly higher
number of total microglia were observed in PS19-TfRMAb-TNFR male mice
compared to the PS19-Saline male mice (A). There was no significant difference in the total number of microglia in the female mice (B). The overall
number of microglia is the sum of the microglia in the cortex, hippocampus, amygdala, and the entorhinal cortex. There was a significant increase
in the overall number of microglia with a smaller soma size (< 50-pixel
units) in the PS19-TfRMAb-TNFR male mice (C) and a significant decrease
in the overall number of microglia with a larger soma size (soma size >
50-pixels) in the PS19-TfRMAb-TNFR, PS19-Etanercept, and WT-Saline
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male mice compared to PS19-Saline male mice (E). There was a significant
decrease in the overall number of microglia with a smaller soma size (<
50-pixel units) in the PS19-TfRMAb-TNFR, PS19-Etanercept and WT-Saline
female mice compared to the PS19-Saline female mice (D). There was no
change in the number of microglia with a larger soma size (soma size >
50-pixels) in the female mice (F). Data are presented as mean ± SEM of n
= 5-7 per treatment group. Two-way ANOVA with repeated measures with
Holm–Sidak’s post hoc test was used to compare to PS19-Saline controls.
*p<0.05, **p<0.01, ****p<0.0001.
Additional file 6: Fig. S5. The protein levels of the BBB tight junction proteins, ZO-1 (A) and claudin-5 (B), in whole-brain homogenates measured
using Western blotting, were not significantly changed in the PS19-Saline
controls compared to the WT-Saline group. Data are presented as mean
± SEM of n = 6-8 per treatment group. A Student’s t-test was used to
compare the two groups.
Additional file 7: Fig. S6. Levels of TNF-α in the plasma (A) and wholebrain homogenates (B) were not significantly different between PS19Saline and PS19-TfRMAb-TNFR and PS19-Etanercept mice, respectively.
We attribute the lack of change in plasma and brain TNF-α levels with
biologic TNF-α inhibitors to the time of plasma and brain sample collection. There was a 10-day lag between the last treatment dose (8 weeks
after treatment initiation) and sample collection due to time for open-field
testing (during week 9; Figure 1A). The plasma elimination half-lives of
TfRMAb-TNFR and etanercept are ~ 4 h and ~13 h, respectively (Figure 5).
Since it takes 6 elimination half-lives (24 h and 78 h for TfRMAb-TNFR and
etanercept, respectively) for a drug to be completely eliminated from
the blood circulation, we do not expect any circulating biologic TNF-α
inhibitor at the time of sacrifice. Another potential reason for the lack of
difference in plasma and brain TNF-α is the use of immunoassays. Since
both the TfRMAb-TNFR and etanercept bind to TNF-α, detection of TNF-α
using immunoassays may be complicated if the TNF-α is still bound to
the biologic TNF-α inhibitor in the brain at the time of mouse sacrifice.
Though this is unlikely considering the elimination half-lives of the drugs,
to rule out any such interference, we measured the protein levels of IĸBα,
which is degraded following TNF-α stimulation and is therefore expected
to increase following TNF-α inhibition, in whole-brain homogenates using
Western blotting (C). The TfRMAb-TNFR-treated PS19 mice had significantly higher (p<0.01) brain IĸBα (an indirect measure of the attenuation
of TNF-α signaling). Similarly, PS19 mice treated with etanercept showed
a trend (p=0.08) towards an increase in brain IĸBα compared to salinetreated PS19 mice, but this data did not reach statistical significance. Data
are presented as mean ± SEM of n = 7-11 mice per treatment group.
Male and female mice were combined due to a lack of sex-related effects.
One-way ANOVA with Holm–Sidak’s post hoc test was used to compare to
PS19-Saline controls. **p<0.01.
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